Pharmaxis Initiates Phase III Trial in Lung Disease
Posted on: Thursday, 20 April 2006, 12:00 CDT
Australian pharmaceutical company Pharmaxis has enrolled the first of 350 patients in its phase III trial evaluating its inhalable dry powder drug candidate Bronchitol in the treatment of the chronic obstructive lung disease, bronchiectasis.
Bronchiectasis is an incurable, degenerative and chronic inflammatory condition of the lungs affecting more than half a million people worldwide.
The trial, which will investigate the safety and effectiveness of the drug, is being conducted at 22 hospitals across Australia, New Zealand, the UK and Northern Ireland.
Two thirds of trial volunteers will receive Bronchitol and the remaining one third will receive a placebo. Patients will be assessed for mucus clearance and quality of life as measured by symptoms, cough severity, exercise capacity and lung function.
This trial follows a successful phase II study in patients with bronchiectasis and the trial design has been constructed following meetings with the European regulatory agencies.
"This pivotal trial for Bronchitol is the final step before registration in Australia, New Zealand and the European Union. When complete, the results of the study should provide sufficient data for a marketing application to be lodged," said Alan Robertson, Pharmaxis CEO.
Full patient recruitment is expected to take about eight months and treatment approximately four months. Results are expected to be available in the June quarter of 2007.
The FDA granted orphan drug status for Bronchitol for the treatment of bronchiectasis in 2005.
Source: Datamonitor
Related Articles
- Repligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
- Pacgen Completes Patient Recruitment for Phase IIb Trial of Antifungal Drug
- Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
- Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
- TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
- Viventia Initiates Patient Treatment in Bladder Cancer Trial
- White-Coat Effect is Virtually Eliminated Using a Non-Drug Hypertension Treatment Device
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds